556: REAL-WORLD EVALUATION OF CEFTOLOZANE/TAZOBACTAM TREATMENT FOR PSEUDOMONAS ACROSS 253 U.S. HOSPITALS
Sign Up to like & getrecommendations! Published in 2019 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000551308.61439.70
Abstract: Learning Objectives: Pseudomonas aeruginosa (PsA) is a significant pathogen associated with severe invasive infections requiring early appropriate therapy, particularly in critically ill patients (pts). Ceftolozane/tazobactam (C/T) is an anti-pseudomonal agent indicated for cUTI and cIAI… read more here.
Keywords: early directed; therapy; 556 real; treatment ... See more keywords